Lidocaine inhalation for local anaesthesia and attenuation of bronchial hyper-reactivity with least airway irritation. Effect of three different dose regimens.
The inhalation of lidocaine attenuates bronchial hyper-reactivity but also causes airway irritation. However, how lidocaine dose and plasma concentration influence relationships are unknown. Accordingly, we evaluated the effects of three concentrations of lidocaine (1, 4, and 10%, total dose of 0.5, 2.0, and 5.0 mg kg-1, respectively) vs. placebo in 15 mild asthmatic patients, selected by their response to a histamine challenge (decrease in FEV1 > 20% to less than 18 mg mL-1 of histamine [PC20]). Baseline lung function, histamine-induced bronchoconstriction, topical anaesthesia, and lidocaine plasma concentrations were obtained. FEV1 following lidocaine inhalation showed the greatest decrease for the highest dose (from 3.79 +/- 0.15-3.60 +/- 0.15; P = 0.0012). Lidocaine inhalation increased baseline PC20 (6.1 +/- 1.3 mg mL-1) significantly (to 11.8 +/- 3.1, 16.1 +/- 3.3, and 18.3 +/- 4.5 mg mL-1, respectively) with no difference between the two highest doses. The duration of local anaesthesia was not significantly different between lidocaine concentrations of 4% and 10%. Thus, lidocaine inhalation, with increasing concentrations of the aerosolized solution, increases initial bronchoconstriction while significant attenuation of bronchial hyper-reactivity is not further enhanced with increasing concentrations from 4 to 10%. Plasma concentrations of lidocaine were always far below the toxic threshold. In conclusion, when local anaesthesia of the airways is required a lidocaine dose of 2.0 mg kg-1 as a 4% solution can be recommended for local anaesthesia and attenuation of bronchial hyper-reactivity with the least airway irritation.
Groeben
H
H
Departments of Anaesthesiology and Intensive Medicine and Gastroenterology, University of Essen, Essen, Germany.
Grosswendt
T
T
Silvanus
M
M
Beste
M
M
Peters
J
J
D000328:Adult; D000403:Airway Resistance / Q000187:drug effects; D018685:Anesthetics, Inhalation / Q000008:administration & dosage* / Q000097:blood; D000779:Anesthetics, Local / Q000008:administration & dosage* / Q000097:blood; D001249:Asthma / Q000503:physiopathology; D001980:Bronchi / Q000187:drug effects*; D016535:Bronchial Hyperreactivity / Q000517:prevention & control*; D001985:Bronchial Provocation Tests; D016085:Bronchoconstrictor Agents; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006632:Histamine; D006801:Humans; D008012:Lidocaine / Q000008:administration & dosage* / Q000097:blood; D008297:Male; D008448:Maximal Expiratory Flow Rate / Q000187:drug effects; D009330:Nebulizers and Vaporizers; D010919:Placebos; D012123:Pulmonary Ventilation / Q000187:drug effects; D018709:Statistics, Nonparametric; D013997:Time Factors; D014797:Vital Capacity / Q000187:drug effects
D018685:Anesthetics, Inhalation; D000779:Anesthetics, Local; D016085:Bronchoconstrictor Agents; D010919:Placebos; D006632:Histamine; D008012:Lidocaine